AC
CBAY

Ascend Capital’s Cymabay Therapeutics CBAY Stock Holding History

Ascend Capital’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-98,800
Closed -$1.28M – 241
2018
Q1 		$1.28M Buy
+98,800
New +$1.23M 0.05% 172

Other funds holding CBAY

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Ascend Capital's CBAY Position: Q2 2018 in Review

Ascend Capital sold out of Cymabay Therapeutics (CBAY) in Q2 2018, closing a stake of 98,800 shares — an estimated $1.28M sold.

Ascend Capital first reported a position in CBAY in Q1 2018 and held it in 1 quarter. The position peaked at $1.28M in Q1 2018. 118 funds tracked by Wall St. Rank hold CBAY as of Q2 2018.

  • Ascend Capital reported no remaining Cymabay Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Ascend Capital sold 98,800 Cymabay Therapeutics shares in Q2 2018, an estimated $1.28M.
  • Ascend Capital first reported a position in Cymabay Therapeutics in Q1 2018 and held it in 1 quarter.
  • Ascend Capital's Cymabay Therapeutics position peaked at $1.28M in Q1 2018.
  • 118 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2018.

Based on Ascend Capital's 13F filing for Q2 2018, filed 13 Aug 2018.